ATE427115T1 - Verwendung von p38/jtv-1 zur behandlung von krebs - Google Patents

Verwendung von p38/jtv-1 zur behandlung von krebs

Info

Publication number
ATE427115T1
ATE427115T1 AT03020344T AT03020344T ATE427115T1 AT E427115 T1 ATE427115 T1 AT E427115T1 AT 03020344 T AT03020344 T AT 03020344T AT 03020344 T AT03020344 T AT 03020344T AT E427115 T1 ATE427115 T1 AT E427115T1
Authority
AT
Austria
Prior art keywords
jtv
protein
binding
fbp
screening
Prior art date
Application number
AT03020344T
Other languages
English (en)
Inventor
Sunghoon Kim
Bum-Joon Park
Original Assignee
Seoul Nat Univ Ind Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seoul Nat Univ Ind Foundation filed Critical Seoul Nat Univ Ind Foundation
Application granted granted Critical
Publication of ATE427115T1 publication Critical patent/ATE427115T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT03020344T 2003-03-03 2003-09-09 Verwendung von p38/jtv-1 zur behandlung von krebs ATE427115T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20030013058 2003-03-03

Publications (1)

Publication Number Publication Date
ATE427115T1 true ATE427115T1 (de) 2009-04-15

Family

ID=32822710

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03020344T ATE427115T1 (de) 2003-03-03 2003-09-09 Verwendung von p38/jtv-1 zur behandlung von krebs

Country Status (7)

Country Link
US (1) US7196068B2 (de)
EP (1) EP1454628B1 (de)
JP (1) JP4351896B2 (de)
KR (1) KR100575251B1 (de)
AT (1) ATE427115T1 (de)
DE (1) DE60326927D1 (de)
ES (1) ES2323580T3 (de)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI297335B (en) 2001-07-10 2008-06-01 Synta Pharmaceuticals Corp Taxol enhancer compounds
TWI252847B (en) 2001-07-10 2006-04-11 Synta Pharmaceuticals Corp Synthesis of taxol enhancers
TWI332943B (en) 2001-07-10 2010-11-11 Synta Pharmaceuticals Corp Taxol enhancer compounds
TWI330079B (en) 2003-01-15 2010-09-11 Synta Pharmaceuticals Corp Treatment for cancers
WO2006009940A1 (en) 2004-06-23 2006-01-26 Synta Pharmaceuticals Corp. Bis(thio-hydrazide amide) salts for treatment of cancers
US9944713B2 (en) 2004-11-24 2018-04-17 Medicinal Bioconvergence Research Center Antibody specific to the AIMP2-DX2
US8003780B2 (en) * 2004-11-24 2011-08-23 Neomics Co., Ltd. AIMP2-DX2 gene and SiRNA targeting AIMP2-DX2
US7459529B2 (en) * 2004-11-24 2008-12-02 Seoul National University Industry Foundation AIMP2-DX2 and its uses
KR20060057992A (ko) * 2004-11-24 2006-05-29 재단법인서울대학교산학협력재단 ｐ38-ＤＸ2 및 이의 용도
US8017654B2 (en) 2005-04-15 2011-09-13 Synta Pharmaceuticals Corp. Combination cancer therapy with bis(thiohydrazide) amide compounds
US20090075941A1 (en) * 2006-04-21 2009-03-19 The Uab Research Foundation Treating neoplasms
TWI440632B (zh) 2006-08-21 2014-06-11 Synta Pharmaceuticals Corp 用於治療增生性疾病的化合物
AU2007290490B2 (en) 2006-08-31 2011-09-08 Synta Pharmaceuticals Corp. Combination with bis(thiohydrazide amides) for treating cancer
US20090093538A1 (en) * 2007-01-03 2009-04-09 Synta Pharmaceuticals Corp Method for treating cancer
JP5771142B2 (ja) * 2008-06-11 2015-08-26 エータイアー ファーマ， インコーポレイテッド チロシル−ｔＲＮＡシンテターゼポリペプチドの血小板新生活性
WO2009158649A1 (en) 2008-06-26 2009-12-30 Atyr Pharma, Inc. Compositions and methods comprising glycyl-trna synthetases having non-canonical biological activities
WO2010099477A2 (en) 2009-02-27 2010-09-02 Atyr Pharma, Inc. Polypeptide structural motifs associated with cell signaling activity
US8756534B2 (en) * 2009-03-16 2014-06-17 Apple Inc. Methods and graphical user interfaces for editing on a multifunction device with a touch screen display
DK3255146T3 (da) 2009-03-16 2019-08-19 Pangu Biopharma Ltd Præparater og fremgangsmåder omfattende histidyl-tRNA-synthetasesplejsningsvarianter med ikke-kanoniske biologiske aktiviteter
US20100310576A1 (en) * 2009-03-31 2010-12-09 Adams Ryan A COMPOSITIONS AND METHODS COMPRISING ASPARTYL-tRNA SYNTHETASES HAVING NON-CANONICAL BIOLOGICAL ACTIVITIES
CA2783731C (en) 2009-12-11 2018-03-27 Atyr Pharma, Inc. Aminoacyl trna synthetases for modulating inflammation
US8828395B2 (en) 2009-12-11 2014-09-09 Atyr Pharma, Inc. Antibodies that bind tyrosyl-tRNA synthetases
US20110150885A1 (en) * 2009-12-11 2011-06-23 Atyr Pharma, Inc. Aminoacyl trna synthetases for modulating hematopoiesis
US8980253B2 (en) 2010-04-26 2015-03-17 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of cysteinyl-tRNA synthetase
US8986681B2 (en) 2010-04-27 2015-03-24 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of threonyl-tRNA synthetases
CN103096911B (zh) 2010-04-27 2018-05-29 Atyr 医药公司 与异亮氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
AU2011248489B2 (en) 2010-04-28 2016-10-06 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of alanyl tRNA synthetases
CN103097523B (zh) 2010-04-29 2016-09-28 Atyr医药公司 与天冬酰胺酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
EP2563383B1 (de) 2010-04-29 2017-03-01 Atyr Pharma, Inc. Innovative entdeckung therapeutischer, diagnostischer und antikörperhaltiger zusammensetzungen im zusammenhang mit proteinfragmenten von valyl-trna-synthetasen
WO2011150279A2 (en) 2010-05-27 2011-12-01 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutaminyl-trna synthetases
CN103108655B (zh) 2010-05-03 2017-04-05 Atyr 医药公司 与丝氨酰‑tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
US9034321B2 (en) 2010-05-03 2015-05-19 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-alpha-tRNA synthetases
CA2797277C (en) 2010-05-03 2021-02-23 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of arginyl-trna synthetases
EP2566496B1 (de) 2010-05-03 2018-02-28 aTyr Pharma, Inc. Innovative entdeckung therapeutischer, diagnostischer und antikörperhaltiger zusammensetzungen im zusammenhang mit proteinfragmenten von methionyl-trna-synthetasen
CA2798139C (en) * 2010-05-04 2019-09-24 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of p38 multi-trna synthetase complex
CA2798301C (en) 2010-05-04 2020-09-15 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutamyl-prolyl-trna synthetases
CN103200953B (zh) 2010-05-14 2017-02-15 Atyr 医药公司 与苯丙氨酰‑β‑tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
CN103096914B (zh) 2010-05-17 2015-08-12 Atyr医药公司 与亮氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
AU2011261486B2 (en) 2010-06-01 2017-02-23 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of lysyl-tRNA synthetases
NZ603811A (en) 2010-07-12 2015-03-27 Atyr Pharma Inc Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of aspartyl-trna synthetases
KR20130102534A (ko) 2010-07-12 2013-09-17 에이티와이알 파마, 인코포레이티드 히스티딜­trna 합성효소의 단백질 단편에 관련된 치료적, 진단적, 및 항체 조성물의 혁신적 발견
EP2593125B1 (de) 2010-07-12 2017-11-01 aTyr Pharma, Inc. Innovative erkennung therapeutischer, diagnostischer und antikörperhaltiger zusammensetzungen in zusammenhang mit proteinfragmenten von glycyl-trna-synthetasen
US8999321B2 (en) 2010-07-12 2015-04-07 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-tRNA synthetases
CN103108650A (zh) 2010-08-25 2013-05-15 Atyr医药公司 与酪氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
CA2812795C (en) 2010-10-06 2021-08-31 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related protein fragments of tryptophanyl trna synthetases
US9714419B2 (en) 2011-08-09 2017-07-25 Atyr Pharma, Inc. PEGylated tyrosyl-tRNA synthetase polypeptides
US9822353B2 (en) 2011-12-06 2017-11-21 Atyr Pharma, Inc. PEGylated aspartyl-tRNA synthetase polypeptides
US9816084B2 (en) 2011-12-06 2017-11-14 Atyr Pharma, Inc. Aspartyl-tRNA synthetases
CA2858613A1 (en) 2011-12-29 2013-08-08 Atyr Pharma, Inc. Aspartyl-trna synthetase-fc conjugates
KR20140123571A (ko) 2012-02-16 2014-10-22 에이티와이알 파마, 인코포레이티드 자가면역 및 염증성 질환의 치료를 위한 히스티딜­ｔｒｎａ 신테타제
KR20130118612A (ko) 2012-04-20 2013-10-30 (주)네오믹스 신규한 아미노피리딘 유도체 및 이의 용도
AU2014233436B2 (en) 2013-03-15 2019-12-05 Atyr Pharma, Inc. Histidyl-tRNA synthetase-Fc conjugates
ES2753650T3 (es) 2014-06-30 2020-04-13 Nat Univ Pusan Ind Univ Coop Found Nuevo compuesto para inhibir la unión entre la proteína DX2 y la proteína p14/ARF, y composición farmacéutica para tratar o prevenir la enfermedad del cáncer que contiene el mismo como ingrediente efectivo
JP2020517638A (ja) 2017-04-20 2020-06-18 エータイアー ファーマ， インコーポレイテッド 肺の炎症を治療するための組成物および方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5000000A (en) * 1988-08-31 1991-03-19 University Of Florida Ethanol production by Escherichia coli strains co-expressing Zymomonas PDC and ADH genes
US5843757A (en) * 1995-08-24 1998-12-01 The Johns Hopkins University Human JTV1 gene overlaps PMS2 gene

Also Published As

Publication number Publication date
EP1454628A2 (de) 2004-09-08
US7196068B2 (en) 2007-03-27
EP1454628A3 (de) 2004-10-13
DE60326927D1 (de) 2009-05-14
JP2005139121A (ja) 2005-06-02
JP4351896B2 (ja) 2009-10-28
ES2323580T3 (es) 2009-07-21
KR100575251B1 (ko) 2006-05-02
US20040175375A1 (en) 2004-09-09
EP1454628B1 (de) 2009-04-01
KR20040078035A (ko) 2004-09-08

Similar Documents

Publication Publication Date Title
DE60326927D1 (de) Verwendung von p38/JTV-1 zur Behandlung von Krebs
Koffa et al. HURP is part of a Ran-dependent complex involved in spindle formation
Takayanagi New immune connections in osteoclast formation
Moon et al. Simvastatin inhibits osteoclast differentiation by scavenging reactive oxygen species
WO2005020921A3 (en) C-kit modulators and methods of use
WO2004006846A3 (en) Receptor-type kinase modulators and methods of use
WO2003093297A3 (en) Protein kinase modulators and methods of use
WO2004091480A3 (en) Tie-2 modulators and methods of use
WO2005030121A3 (en) Compounds, compositions and methods
WO2005112932A3 (en) Raf modulators and methods of use
JO2373B1 (en) W-carboxy-aryl diphenyl urease substitutes used as RAV inhibitors
GEP20043363B (en) Indazole Compounds, Pharmaceutical Compositions, and Methods for Inhibiting Cell Proliferation
DE60222302D1 (de) Inhibitoren von mitotischem kinesin
EA200602100A1 (ru) Соединения и способы для ингибирования митотической прогрессии
WO2005117909A3 (en) Kinase modulators and methods of use
WO2005040355A3 (en) Tao kinase modulators and methods of use
WO2005023202A3 (en) Tumor suppressor lkb1 kinase directly activates amp-activated kinase
ATE397000T1 (de) Tetrahydropyridothiophenen zur verwendung in der behandlung von krebs
Gheysarzadeh et al. STAT5 reactivation by catechin modulates H 2 O 2-induced apoptosis through miR-182/FOXO1 pathway in SK-N-MC cells
Alaikov et al. Antineoplastic and anticlastogenic properties of curcumin
Juengel et al. Alterations of the gene expression profile in renal cell carcinoma after treatment with the histone deacetylase-inhibitor valproic acid and interferon-alpha
WO2004083235A3 (en) Tie-2 modulators and methods of use
Matsubara et al. Cbp recruitment of Csk into lipid rafts is critical to c‐Src kinase activity and bone resorption in osteoclasts
Iuchi et al. Identification of the small interstitial deletion at chromosome band 1p34–p35 and its association with poor outcome in oligodendroglial tumors
WO2005089730A3 (en) Dna pkinase inhibitors for treating cancer and diabetes

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties